Shield has announced that results from the ACCRUFeR® paediatric pharmacokinetic (PK) study are to be presented at the American Society of Hematology (ASH) conference next month. The PK sub-study was part of the positive Phase 3 FORTIS trial that confirmed ferric maltol’s suitability for iron replacement in children one month and older, and that was pivotal in supporting the Clinical Supplement assigned Priority Review by the US FDA to extend the indication for ACCRUFeR to include adolescents age ....
